Study pinpoints ‘critical time windows' for illnesses that pose dementia risk
Strokes or the onset of mental health conditions such as anxiety and depression between 55 and 70 could also increase risk two-fold, according to research.
Experts at the University of Oxford said up to 80% of dementia patients suffer from two or more chronic health conditions, but there is a 'lack of understanding' when it comes to specific illnesses, age of onset and the link to dementia.
They identified 'critical time windows' in which certain illnesses pose the greatest risk to patients.
For the study, published in Brain Communications, researchers analysed data from 282,712 people using the UK Biobank and looked at patterns for 46 chronic health conditions.
They found that heart conditions such as heart disease and atrial fibrillation, as well as diabetes, before the age of 55 was most strongly linked to dementia risk.
However, from 55 to 70 years of age, mental health conditions such as anxiety and depression, as well as conditions such as stroke, increased the risk of dementia two-fold.
Sana Suri, an associate professor and Oxford Brain Sciences senior fellow, said: 'Although we knew that multimorbidity increased the risk of dementia, it was unclear which combinations of health conditions had the most impact and in what sequence.
'This study has identified how specific illnesses tend to co-exist with each other, and also the critical time windows in which they could pose the greatest risk.'
Elsewhere, the study suggests people who have conditions such as heart disease and diabetes in middle age, followed later by conditions such as stroke and mental health disorders were at the greatest risk of developing dementia.
Ms Suri said the presence of other illnesses should be taken into account when estimating a person's risk of developing dementia, and could help develop strategies that aim to reduce risk at certain points in life.
She added: 'This study identified associations between multimorbidity and dementia risk but we need to understand more about why this happens.
'We also need to try to replicate the study in more diverse groups of people to ensure the results are representative of the population.
'Future studies could examine whether efforts to manage or prevent cardiovascular problems in early-to-midlife, followed by mental health and neurological disorders when people are in their fifties and sixties, might reduce the risk of dementia.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
6 minutes ago
- The Sun
Thousands of hay fever sufferers will soon be prescribed a new treatment on the NHS
THOUSANDS of hay fever sufferers will soon be prescribed a new treatment on the NHS. An under-the-tongue tablet — sold under brand name Itulazax — trains the body to tolerate more pollen through exposure. And trials show it can significantly reduce the worst allergy symptoms. NHS spending watchdog Nice has now recommended it for people whose hay fever persists after basic treatment. Nice's medicines evaluations chief Helen Knight said: "This treatment will help improve people's quality of life. "Severe tree pollen allergies trap people indoors during beautiful weather and disrupt their work, education and family life. "The daily tablet offers genuine long-term relief rather than just managing symptoms." However, it only works on those with a birch pollen allergy — which is about a quarter of hay fever sufferers, estimated to be 27,000 people. The NHS in England will offer it within three months of Nice publishing its final guidance. Amena Warner, head of clinical services at Allergy UK, said: "Many people don't realise how awful it is having an itchy, runny nose, sneezing episodes or itchy, irritated eyes in the pollen season. "We frequently hear from people who avoid time outdoors, keep doors and windows shut, check pollen counts and try and minimise any exposure, which takes a significant toll on their physical and emotional wellbeing. "Nice's recommendation is so important because it provides a genuine opportunity for people to manage the root cause of their pollen allergy, offering the chance to break free from this burden and enjoy a better quality of life." hayfever recommendations from a boots pharmacist 1
The Sun
6 minutes ago
- The Sun
Pharmacy worker who stole weight loss drug Ozempic and sold it on black market is spared jail
A PHARMACY worker who stole weight loss drug Ozempic and sold it on the black market was spared jail yesterday. Akshay Sennik, 31, took two £75 pens of the jabs from a stock room and flogged them for £100. He was arrested after colleagues noticed 'shrinkage' in the drug's stockpile, JPs heard. Dispensing assistant Sennik, who had worked for nine years in healthcare, had no previous criminal record. He was sentenced to a two-year conditional discharge by Bromley magistrates after they heard his offending was motivated by alcoholism. Sennik, whose address was given as his parents' home in Chislehurst, South East London, pleaded guilty earlier. Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines. 1
The Independent
35 minutes ago
- The Independent
ME care reforms promised after woman's tragic death
The government has pledged to overhaul care for hundreds of thousands of people living with chronic fatigue syndrome, acknowledging that many "struggle" to access appropriate support. The Department of Health and Social Care (DHSC) stated its intention to publish a new plan, asserting it is "committed to changing attitudes and transforming care" for individuals with Myalgic Encephalomyelitis /Chronic Fatigue Syndrome (ME/CFS). She had suffered with ME for a decade before dying at her home in Exeter in October 2021 from severe malnutrition. Her inquest revealed she had been admitted to the Royal Devon and Exeter Hospital three times in the year of her death for malnutrition treatment. The 10-day hearing detailed her final months, during which she was confined to bed, unable to chew food, and struggled to drink due to being unable to sit up. Miss Boothby-O'Neill, the daughter of Sean O'Neill, a journalist with The Times newspaper, had been suffering from fatigue since the age of 13, which got worse after she completed her A-levels. Deborah Archer, now an area coroner for Devon, Plymouth and Torbay, concluded Miss Boothby-O'Neill had died from natural causes 'because of severe myalgic encephalomyelitis (ME)'. Last year she wrote to the Government to highlight a lack of specialist beds, 'extremely limited' training for doctors and lack of available funding for research and treatment of the condition. On Tuesday, the Government said that it has created a plan which 'outlines clear steps to improve care for patients, by investing in research and offering access to care in the community'. The Department of Health and Social Care (DHSC) acknowledged that many people with the condition 'currently struggle to access appropriate care tailored to their complex condition'. The plan, which is expected to be published on Tuesday, will include new training for NHS workers, DHSC said. And the document will also include funding for research, the DHSC said. Public health minister Ashley Dalton, said: 'ME/CFS is a debilitating illness that can severely limit patients' ability to participate in everyday activities, maintain employment, or enjoy family and social life. 'Today's plan will help tackle the stigma and lack of awareness of this condition through improved training for NHS staff. 'And through our neighbourhood health services, we will ensure patients suffering from the effects of ME/CFS can access quality care, closer to home, as pledged in our 10-Year Health Plan. But Action for ME said that the plan 'does not go far enough'. Sonya Chowdhury, chief executive of the charity, said: 'We appreciate the time DHSC has put into the delivery plan and their engagement with us and the ME community throughout. 'However, the plan simply does not go far enough. We are at the stage now where we need more than rhetoric, we need to take a strategic approach if we want a different outcome. What is proposed in the plan will not offer this. 'We must have a funded, dedicated research hub to leverage our world-leading life sciences sector to unlock treatments and ultimately cures for ME. 'Without a commitment to better co-ordinate research, people with ME will continue to be neglected, overlooked and, for many, confined to their homes. 'ME charities have been calling for this funding to be accelerated for years and we are still not seeing a strategic approach to address this historic shortfall. Once again, it feels like people with ME have been ignored.'
